Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β₂-Agonist Dual Therapy in a Primary Care Setting in England

References

• Soriano JB, Polverino F, Cosio BG. What is early COPD and why is it important? Eur Respir J. 2018;52(6):1801448. doi:10.1183/13993003.01448-2018
   PubMed Web of Science ®Google Scholar
• Baraldo S, Turato G, Saetta M. Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration. 2012;84(2):89–97. doi:10.1159/000341382
   PubMed Web of Science ®Google Scholar
• G. B. D. Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• British Lung Foundation. Chronic obstructive pulmonary disease (COPD) statistics; 2021. Available from: https://statistics.blf.org.uk/copd. Accessed October 2021.
   Google Scholar
• Health and Safety Executive. Work-related chronic obstructive pulmonary disease (COPD) statistics in Great Britain; 2020. Available from: https://www.hse.gov.uk/statistics/causdis/copd.pdf. Accessed October 2020.
   Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S234942
   PubMed Web of Science ®Google Scholar
• Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20(1):11–23. doi:10.5588/ijtld.15.0472
   PubMed Web of Science ®Google Scholar
• Brien SB, Lewith GT, Thomas M. Patient coping strategies in COPD across disease severity and quality of life: a qualitative study. NPJ Prim Care Respir Med. 2016;26:16051. doi:10.1038/npjpcrm.2016.51
   PubMed Web of Science ®Google Scholar
• Wang Q, Ji W, He K, et al. Genetic analysis of common variants in the ZNF804A gene with schizophrenia and major depressive disorder. Psychiatr Genet. 2018;28(1):1–7. doi:10.1097/ypg.0000000000000185
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed October 2021.
   Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2018. Available from: https://www.nice.org.uk/guidance/ng115. Accessed October 2021.
   Google Scholar
• Novartis Pharmaceuticals UK Ltd. Ultibro Breezhaler SmPC; 2020. Available from: https://www.medicines.org.uk/emc/medicine/29533. Accessed October 2021.
   Google Scholar
• AstraZeneca UK Ltd. Duaklir Genuair SmPC; 2021. Available from: https://www.medicines.org.uk/emc/medicine/29652. Accessed October 2021.
   Google Scholar
• Boehringer Ingelheim Limited. Spiolto Respimat SmPC; 2020. Available from: https://www.medicines.org.uk/emc/medicine/30495. Accessed October 2021.
   Google Scholar
• GlaxoSmithKline UK. Anoro Ellipta SmPC; 2021. Available from: https://www.medicines.org.uk/emc/medicine/28949. Accessed October 2021.
   Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.001
   PubMed Web of Science ®Google Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92. doi:10.1186/s12931-015-0250-2
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.00136014
   PubMed Web of Science ®Google Scholar
• Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494. doi:10.1183/09031936.00200212
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209. 10.1016/S2213-2600(13) 70052–3. doi:10.1016/S2213-2600(13)70052-3
   Web of Science ®Google Scholar
• Wolf A, Dedman D, Campbell J, et al. Data resource profile: clinical practice research datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740–1740g. doi:10.1093/ije/dyz034
   PubMed Web of Science ®Google Scholar
• Nissen F, Morales DR, Mullerova H, Smeeth L, Douglas IJ, Quint JK. Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). BMJ Open. 2017;7(8):e017474. doi:10.1136/bmjopen-2017-017474
   PubMed Web of Science ®Google Scholar
• Curtis LA. Burns, Amanda Unit costs of health and social care; 2019.
   Google Scholar
• National Health Services. Drug tariff part VIII. Available from: https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff/drug-tariff-part-viii. Accessed October 2021.
   Google Scholar
• National Health Services England. National tariff 2019/20: documents and policies. Available from: https://www.england.nhs.uk/publication/past-national-tariffs-documents-and-policies/. Accessed October 2021.
   Google Scholar
• Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, Reason T. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10(2):89–104. doi:10.1177/1753465815624612
   PubMed Web of Science ®Google Scholar
• Siddiqui MK, Shukla P, Jenkins M, et al. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD. Ther Adv Respir Dis. 2019;13:1753466619894502. doi:10.1177/1753466619894502
   Web of Science ®Google Scholar
• Lee HW, Park J, Jang EJ, Lee C-H. Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. Respir Res. 2020;21(1):1–15. doi:10.1186/s12931-020-01540-8
   PubMed Web of Science ®Google Scholar
• Thomas M, Radwan A, Stonham C, Marshall S. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD. 2014;11(3):300–309. doi:10.3109/15412555.2013.841671
   PubMedGoogle Scholar
• Punekar YS, Wurst K, Shukla A. Resource use and costs up to two years post diagnosis among newly diagnosed COPD patients in the UK primary care setting: a retrospective cohort study. COPD. 2015;12(3):267–275. doi:10.3109/15412555.2014.933953
   PubMedGoogle Scholar
• Britton M. The burden of COPD in the UK: results from the confronting COPD survey. Respir Med. 2003;97(Suppl C):S71–79. doi:10.1016/s0954-6111(03)80027-6
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836. doi:10.1093/ije/dyv098
   PubMed Web of Science ®Google Scholar
• Quint JK, Müllerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ open. 2014;4(7):e005540. doi:10.1136/bmjopen-2014-005540
   PubMed Web of Science ®Google Scholar
• Kim C, Yoo K, Rhee C, et al. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberculosis Lung Dis. 2014;18(6):737–743. doi:10.5588/ijtld.13.0634
   PubMed Web of Science ®Google Scholar